Ostarine (MK-2866) and the psyche: mood, sleep, anxiety

When people talk about the risks of ostarine, they usually mention the liver, lipids and suppression of testosterone. The psyche is discussed less often — and mostly at the level of forum stories. The editorial team tried to separate the documented from the assumed: what is known about the effect of ostarine on mood, sleep and anxiety, where such symptoms may come from, and why the absence of data does not mean the absence of risk.

Androgens and the brain: starting points

Androgen receptors are present not only in the muscles and prostate but also in many areas of the brain: the hypothalamus, amygdala, hippocampus, cortex. Through them testosterone participates in the regulation of libido, motivation, aggressiveness, the stress response and, in part, cognitive functions. Part of these effects, however, is realized through estradiol, which is formed from testosterone directly in nervous tissue with the participation of aromatase.

Experience with anabolic steroids shows that the influence of androgens on the psyche is real. A controlled study by Pope and Katz (1994) among athletes recorded in some steroid users episodes of hypomania, irritability and aggressiveness during use, as well as depressive symptoms after withdrawal. Subsequent reviews confirmed that these effects are individually very variable and partly depend on the dose.

Ostarine is a nonsteroidal agonist of the androgen receptor. It does not aromatize, that is, it is not converted into estradiol, and it is not converted into dihydrotestosterone. Hence its direct effect on the brain may differ from that of steroids. However, the ability of this specific molecule to penetrate the central nervous system and its activity in different areas of the brain in humans have not been systematically studied.

This is a key point: most claims like "SARMs do not affect the psyche" rest not on data but on their absence. Special studies of ostarine with psychometric scales, assessment of sleep or anxiety have, as far as the editorial team is aware, not been published.

What clinical studies have shown

The main clinical data on enobosarm (ostarine) come from phase II studies in older people (Dalton et al., 2011) and in cancer patients (Dobs et al., 2013). In these works the drug was tolerated generally satisfactorily, and the frequency of adverse events did not differ substantially from placebo. No serious psychiatric events related to the drug were described in the publications.

However, the limitations should be taken into account. First, mental state was not an endpoint: side effects were recorded by a general scheme rather than by specialized questionnaires. Second, doses in these studies were 1–3 mg per day, and the duration — several months. Third, the participants were older people or cancer patients, not young men who train.

By contrast, informal use often occurs at doses that substantially exceed those studied, in combination with other substances and without medical oversight. Transferring the conclusions of clinical studies to such conditions is incorrect.

The only source of data on "real" use remains surveys. In a cross-sectional online survey of SARM users (Efimenko et al., 2022), respondents reported, among adverse effects, in particular, mood changes. Such data have low evidentiary value: there is no control group, the actual composition of the products is unknown, and the answers depend on self-assessment.

Indirect mechanisms: the hormonal "dip"

The most substantiated pathway of ostarine's effect on the psyche is indirect. Like other androgen receptor agonists, ostarine, by the mechanism of negative feedback, reduces the production of luteinizing and follicle-stimulating hormones. The consequence is a decrease in one's own testosterone, and hence also of estradiol, which is formed from it.

While the SARM is present in the body, it partially "substitutes" for androgenic action in the muscles. But ostarine does not aromatize, so the estrogenic component of the hormonal background may remain reduced. For men, low estradiol is associated with reduced libido, worsened well-being and, according to some data, mood changes.

An even more vulnerable period is after stopping use. The drug is eliminated, and one's own hormonal axis does not recover at once. During this time a person may be in a state of functional hypogonadism: fatigue, apathy, low mood, a drop in libido, irritability. These symptoms are easy to confuse with "overtraining" or ordinary stress.

Clinicians who work with androgen-induced hypogonadism after steroids describe exactly such a picture, and it is logical to expect it in a milder or similar form after SARMs. There are, however, no direct comparative studies, so it is impossible to speak of the duration or frequency of such states after ostarine.

Sleep, anxiety and the role of impurities

As for sleep, there are no direct data on ostarine. It is known that both a testosterone deficiency and supraphysiological levels of androgens can worsen sleep quality; during testosterone therapy, for example, an exacerbation of obstructive sleep apnea has been described. Whether this applies to SARMs is unknown, so the editorial team regards such assumptions only as hypotheses.

The anxiety and insomnia that users report often have a different nature — the product's composition. A study by Van Wagoner and co-authors (2017) showed that a significant proportion of online products sold as SARMs contained not the declared substance, a different SARM, other unregistered compounds, or no active substance at all. A person who thinks they are taking "pure ostarine" actually does not know what is entering their body.

In addition, SARMs are often combined with pre-workout complexes, fat burners with stimulants, large doses of caffeine. It is precisely stimulants that are the most obvious cause of anxiety, palpitations and difficulty falling asleep. Attributing these effects to ostarine without accounting for the whole "set" is incorrect.

Finally, it is worth considering the psychological context. Taking an illegal or gray substance, expecting a quick result, comparing oneself with others, and — for athletes — fear of doping control can in themselves heighten anxiety. The editorial team emphasizes: even without a biological action these factors are real.

Warning signs and when to see a doctor

Since data on the psychiatric effects of ostarine are limited, it is important to know which changes of state require attention regardless of their cause. You should see a doctor if you notice:

• persistently low mood, loss of interest in usual activities for more than two weeks;
• pronounced irritability, outbursts of aggression, conflicts that were not there before;
• anxiety, panic attacks, palpitations, sleep disturbances that do not go away;
• a sharp drop in libido, erectile dysfunction, pronounced fatigue after stopping use;
• any thoughts of self-harm — this is a reason to seek help immediately.

It is worth honestly informing the doctor about the intake of any substances, including SARMs. This makes it possible to order the right tests: testosterone, LH, FSH, estradiol, SHBG, prolactin, liver indicators and a lipid panel. Without this information the symptoms may be interpreted incorrectly, and treatment delayed.

Independent attempts to "fix" the condition with other prescription drugs written about on forums only complicate the situation and may add new risks. Correction of the hormonal background should be handled by an endocrinologist or andrologist.

If the symptoms arose while taking a product of unknown composition, it is useful to keep the packaging: in some cases this helps to understand what the body was dealing with.

Editorial conclusions

There is no direct clinical evidence that ostarine causes mental disorders, but there is also no evidence of safety for the psyche: this area simply has not been specifically studied.

The most substantiated mechanism is indirect: suppression of one's own testosterone and estradiol during use and especially after it, which can manifest as low mood, fatigue, a drop in libido and, probably, worsened sleep.

Anxiety and insomnia are often explained by impurities and accompanying stimulants. The unknown composition of products makes any predictions about mental state unreliable.

For a deeper understanding of the topic we recommend our materials on the history of ostarine's development, on the interaction of ostarine with other substances, and on the effect of ligandrol on the psyche.

References

1. Dalton JT, Barnette KG, Bohl CE, et al. The selective androgen receptor modulator GTx-024 (enobosarm) improves lean body mass and physical function in healthy elderly men and postmenopausal women: results of a double-blind, placebo-controlled phase II trial. J Cachexia Sarcopenia Muscle. 2011;2(3):153–161.
2. Dobs AS, Boccia RV, Croot CC, et al. Effects of enobosarm on muscle wasting and physical function in patients with cancer: a double-blind, randomised controlled phase 2 trial. Lancet Oncol. 2013;14(4):335–345.
3. Pope HG Jr, Katz DL. Psychiatric and medical effects of anabolic-androgenic steroid use: a controlled study of 160 athletes. Arch Gen Psychiatry. 1994;51(5):375–382.
4. Kanayama G, Hudson JI, Pope HG Jr. Long-term psychiatric and medical consequences of anabolic-androgenic steroid abuse: a looming public health concern? Drug Alcohol Depend. 2008;98(1–2):1–12.
5. Efimenko IV, Valancy D, Dubin JM, Ramasamy R. Adverse effects and potential benefits among selective androgen receptor modulators users: a cross-sectional survey. Int J Impot Res. 2022.
6. Van Wagoner RM, Eichner A, Bhasin S, et al. Chemical composition and labeling of substances marketed as selective androgen receptor modulators and sold via the internet. JAMA. 2017;318(20):2004–2010.
7. Rahnema CD, Lipshultz LI, Crosnoe LE, et al. Anabolic steroid-induced hypogonadism: diagnosis and treatment. Fertil Steril. 2014;101(5):1271–1279.